APLLTDPharmaceuticals
Alembic Pharmaceuticals Ltd — Cash Flow Statement
₹673.55
-2.97%
Alembic Pharmaceuticals Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | -475.65 Cr | 475.73 Cr | 280.54 Cr | 126.71 Cr | — |
| Capital Expenditure | -563.62 Cr | -327.47 Cr | -443.41 Cr | -425.64 Cr | — |
| End Cash Position | 83.48 Cr | 120.21 Cr | 75.48 Cr | 61.09 Cr | — |
| Beginning Cash Position | 120.21 Cr | 75.48 Cr | 61.09 Cr | 98.06 Cr | — |
| Changes In Cash | -36.73 Cr | 44.72 Cr | 14.40 Cr | -36.97 Cr | — |
| Financing Cash Flow | 443.71 Cr | -437.87 Cr | -261.96 Cr | -217.35 Cr | — |
| Net Other Financing Charges | -0.04 Cr | -0.02 Cr | 1.53 Cr | -0.05 Cr | — |
| Interest Paid Cff | -78.59 Cr | -49.37 Cr | -49.70 Cr | -51.92 Cr | — |
| Cash Dividends Paid | -216.22 Cr | -157.25 Cr | -196.56 Cr | -275.19 Cr | — |
| Net Issuance Payments Of Debt | 765.12 Cr | -205.41 Cr | 5.87 Cr | 129.98 Cr | — |
| Net Short Term Debt Issuance | 765.12 Cr | -205.41 Cr | 205.87 Cr | 429.98 Cr | — |
| Investing Cash Flow | -568.41 Cr | -320.61 Cr | -447.59 Cr | -371.97 Cr | — |
| Net Other Investing Changes | 9.77 Cr | -0.01 Cr | 0.01 Cr | 1.38 Cr | — |
| Interest Received Cfi | 5.49 Cr | 1.99 Cr | 0.33 Cr | 1.73 Cr | — |
| Dividends Received Cfi | 1.08 Cr | 1.64 Cr | 0.61 Cr | 2.88 Cr | — |
| Net Investment Purchase And Sale | -21.13 Cr | -8.32 Cr | -7.00 Cr | 47.68 Cr | — |
| Purchase Of Investment | -21.13 Cr | -8.32 Cr | -7.00 Cr | -139.29 Cr | — |
| Net PPE Purchase And Sale | -553.85 Cr | -315.91 Cr | -441.54 Cr | -425.64 Cr | — |
| Sale Of PPE | 9.77 Cr | 11.56 Cr | 1.87 Cr | — | — |
| Purchase Of PPE | -563.62 Cr | -327.47 Cr | -443.41 Cr | -425.64 Cr | — |
| Operating Cash Flow | 87.97 Cr | 803.20 Cr | 723.95 Cr | 552.35 Cr | — |
| Taxes Refund Paid | -71.40 Cr | -19.85 Cr | -60.70 Cr | -123.43 Cr | — |
| Change In Working Capital | -921.36 Cr | -95.65 Cr | -57.56 Cr | -367.34 Cr | — |
| Change In Other Current Liabilities | -1.50 Cr | -1.54 Cr | -84.18 Cr | 43.22 Cr | — |
| Change In Other Current Assets | -49.06 Cr | -17.58 Cr | 127.14 Cr | 128.19 Cr | — |
| Change In Payable | 146.15 Cr | 56.04 Cr | -28.17 Cr | 36.67 Cr | — |
| Change In Inventory | -644.60 Cr | -168.28 Cr | 134.44 Cr | -123.55 Cr | — |
| Change In Receivables | -395.00 Cr | 39.05 Cr | -222.88 Cr | -469.62 Cr | — |
| Other Non Cash Items | 72.81 Cr | 54.10 Cr | 148.28 Cr | 96.13 Cr | — |
| Provisionand Write Offof Assets | 3.46 Cr | 5.36 Cr | 0.00 | 7.30 Cr | — |
| Depreciation And Amortization | 278.58 Cr | 272.67 Cr | 275.43 Cr | 286.78 Cr | — |
| Depreciation | 278.58 Cr | 272.67 Cr | 275.43 Cr | 286.78 Cr | — |
| Gain Loss On Investment Securities | -1.48 Cr | -4.40 Cr | -0.75 Cr | -3.42 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 24.27 Cr | -40.15 Cr | 29.06 Cr | 36.45 Cr | — |
| Gain Loss On Sale Of PPE | -3.26 Cr | -1.70 Cr | 4.70 Cr | — | — |
| Net Income From Continuing Operations | 707.18 Cr | 631.83 Cr | 354.59 Cr | 625.39 Cr | — |
| Repayment Of Debt | — | 0.00 | -200.00 Cr | -300.00 Cr | -379.27 Cr |
| Other Cash Adjustment Outside Changein Cash | — | 0.01 Cr | -0.01 Cr | — | 0.01 Cr |
| Effect Of Exchange Rate Changes | — | 0.00 | 0.00 | 0.00 | -0.93 Cr |
| Net Long Term Debt Issuance | — | 0.00 | -200.00 Cr | -300.00 Cr | -379.27 Cr |
| Long Term Debt Payments | — | 0.00 | -200.00 Cr | -300.00 Cr | -379.27 Cr |
| Sale Of Investment | — | — | 0.00 | 186.97 Cr | — |
| Issuance Of Capital Stock | — | — | — | 0.00 | 734.08 Cr |
| Net Common Stock Issuance | — | — | — | 0.00 | 734.08 Cr |
| Common Stock Issuance | — | — | — | 0.00 | 734.08 Cr |
| Net Business Purchase And Sale | — | — | — | — | -0.46 Cr |
| Purchase Of Business | — | — | — | — | -0.46 Cr |
| Pension And Employee Benefit Expense | — | — | — | — | -1.25 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Alembic Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.